Literature DB >> 24493726

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

Evan J Lipson1, Mabel A Bodell2, Edward S Kraus2, William H Sharfman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24493726      PMCID： PMC4870592          DOI： 10.1200/JCO.2013.49.2314

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

Authors:  P S Linsley; J Bradshaw; J Greene; R Peach; K L Bennett; R S Mittler
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  Different regulatory and cytotoxic CD4+ T lymphocyte profiles in renal transplants with antibody-mediated chronic rejection or long-term good graft function.

Authors:  Fulvia Giaretta; Stefania Bussolino; Silvia Beltramo; Fabrizio Fop; Maura Rossetti; Maria Messina; Vincenzo Cantaluppi; Andrea Ranghino; Elisa Basso; Giovanni Camussi; Giuseppe Paolo Segoloni; Luigi Biancone
Journal:  Transpl Immunol       Date:  2012-11-22       Impact factor: 1.708

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 5.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

6.  Melanoma in solid organ transplant recipients.

Authors:  F O Zwald; L J Christenson; E M Billingsley; N C Zeitouni; D Ratner; J Bordeaux; M J Patel; M D Brown; C M Proby; S Euvrard; C C Otley; T Stasko
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

Review 7.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Authors:  Karl S Peggs; Sergio A Quezada; James P Allison
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

10.  Outcomes of melanoma in recipients of solid organ transplant.

Authors:  Daniel C Dapprich; Roger H Weenig; Audrey L Rohlinger; Amy L Weaver; Katherine K Lim Quan; James H Keeling; John S Walsh; Clark C Otley; Leslie J Christenson
Journal:  J Am Acad Dermatol       Date:  2008-06-16       Impact factor: 11.527
View more
  44 in total

Review 1.  Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity.

Authors:  Dibyendu Samanta; Steven C Almo
Journal:  Cell Mol Life Sci       Date:  2014-10-19       Impact factor: 9.261

Review 2.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

3.  Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

Authors:  Lewis Au; Aine O'Reilly; James Larkin
Journal:  Melanoma Manag       Date:  2017-08-02

Review 4.  Renal complications of immune checkpoint blockade.

Authors:  Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal:  Curr Probl Cancer       Date:  2016-12-19       Impact factor: 3.187

5.  Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus.

Authors:  Rosie Qin; April Ks Salama
Journal:  Melanoma Manag       Date:  2015-11-24

Review 6.  Current status of alloimmunity.

Authors:  Thiago J Borges; Naoka Murakami; Leonardo V Riella
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

7.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

Review 8.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

Review 9.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 10.  High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Clinical Review.

Authors:  Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day
Journal:  Ann Surg Oncol       Date:  2021-06-30       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.